• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: In Situ vs Uterine Exteriorization for Cesarean Repair

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • A frequently cited reason to avoid exteriorization for uterine repair following cesarean delivery relates to potential for nausea and vomiting
    • Phenylephrine infusion with spinal anesthesia decreases the risk of hypotension and nausea
  • Mireault et al. compared exteriorization vs in situ repair using a standardized anesthetic protocol with the goal of assessing impact on patient nausea and vomiting

METHODS:

  • Randomized double-blind controlled trial (RCT)
  • Participants
    • Women undergoing elective cesarean delivery
    • Exclusion: Risk factors for uterine atony and PPH | Preoperative nausea and vomiting | BMI >35 kg/m2
  • Standardized anesthetic protocol used for all patients
    • 1,000 mL of Lactated Ringer’s (over 5 to 10 minutes) then 300 mL/hour infusion
    • Spinal placed with patient in sitting position (hyperbaric bupivacaine, fentanyl and morphine)
    • Patient then placed in supine position with left uterine displacement
    • Phenylephrine perfusion: 0.5 micrograms/kg of lean body weight/min
  • Interventions
    • Exteriorization
    • In situ uterine repair
  • Statistical analysis
    • Power: 80 patients per group was needed to demonstrate a 50% reduction in intraoperative nausea and vomiting with in situ repair
  • Primary outcome
    • Postdelivery intraoperative nausea and vomiting using a 4-point scale (0 to 3)
    • Patients asked to rate nausea at time of skin incision, hysterotomy, placental delivery, beginning of uterine repair, beginning of fascia repair (last 2 time points used to assess nausea related to repair)
    • Patient and data collector were blinded
  • Additional data collected included
    • Hypotensive episodes | Tachycardia | Antiemetics | Vasopressor boluses | Length of surgery | Blood loss

RESULTS:

  • 180 women randomized
    • Exteriorization: 90 women
    • In situ repair: 90 women
  • Nausea and vomiting were more common in the exteriorization group (p=0.01)
    • Exteriorization: 39%
    • In situ repair: 22%
  • The exteriorization group more commonly experienced
    • Hypotension (p<0.001)
      • Exteriorization: 80%
      • In situ repair: 50%
    • Tachycardia (p=0.02)
      • Exteriorization: 33%
      • In situ repair: 17%
  • More phenylephrine boluses were administered to the exteriorization group (p<0.001)
    • Exteriorization: median 4 boluses
    • In situ repair: median 2 boluses
  • No differences were found for the following
    • Duration of surgery
    • Blood loss
    • Postoperative hemoglobin decline

CONCLUSION:

  • When using standard anesthesia protocols that includes phenylephrine, in situ uterine repair is associated with less postoperative nausea and vomiting, compared to exteriorization
  • There was no difference in blood loss or surgery duration

Learn More – Primary Sources:

Uterine Exteriorization Compared With In Situ Repair of Hysterotomy After Cesarean Delivery: A Randomized Controlled Trial

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Practical info on evidence based medicine for your women's healthcare practice
Is it better to leave the uterus in the abdominal cavity or exteriorize it following C-section?
Does General Anesthesia for Cesarean Increase Odds of Severe Postpartum Depression?
How Well Does IV Acetaminophen Control Post-Op Cesarean Pain?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site